FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:1772-1777 October 21, 2004 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Just when scientists thought they had figured out the fundamental mechanisms through which gene expression is regulated, studies of the nematode Caenorhabditis elegans¹ revealed the existence of a pathway, now known as RNA interference (RNAi), that silences gene expression by promoting degradation of RNA. Scientists have discovered ways to control RNAi in order to regulate gene expression in a variety of biologic systems, and they are researching ways to harness RNAi to interrupt disease processes such as those caused by human immunodeficiency virus type 1 (HIV-1), hepatitis viruses, and influenzavirus.

Discovery of RNAi

Events leading up to the discovery of RNAi illustrate the . . . [Full Text of this Article]

Mechanism of Gene Silencing

Therapeutic Applications

Oncogenesis

Viral Hepatitis

Infectious Diseases

Prospects for Therapy

Obstacles to Therapy

Conclusions

Source Information

From the Program in Molecular Medicine, University of Massachusetts Medical School, Worcester.

Address reprint requests to Dr. Stevenson at the Program in Molecular Medicine, University of Massachusetts Medical School, 373 Plantation St., Suite 319, Worcester, MA 01605, or at mario.stevenson@umassmed.edu.

This article has been cited by other articles:

• Gimenez-Barcons, M., Clotet, B., Martinez, M. A. (2007). Endoribonuclease-Prepared Short Interfering RNAs Induce Effective and Specific Inhibition of Human Immunodeficiency Virus Type 1 Replication. J. Virol. 81: 10680-10686 [Abstract] [Full Text]  
• Narang, A. S., Mahato, R. I. (2006). Biological and biomaterial approaches for improved islet transplantation.. Pharmacol. Rev. 58: 194-243 [Abstract] [Full Text]  
• Paulson, H. (2006). RNA interference as potential therapy for neurodegenerative disease: Applications to inclusion-body myositis?. Neurology 66: S114-S117 [Abstract] [Full Text]  
• Sabariegos, R., Gimenez-Barcons, M., Tapia, N., Clotet, B., Martinez, M. A. (2006). Sequence Homology Required by Human Immunodeficiency Virus Type 1 To Escape from Short Interfering RNAs. J. Virol. 80: 571-577 [Abstract] [Full Text]  
• Trian, T., Girodet, P.-O., Ousova, O., Marthan, R., Tunon-de-Lara, J. M., Berger, P. (2006). RNA Interference Decreases PAR-2 Expression and Function in Human Airway Smooth Muscle Cells. Am. J. Respir. Cell Mol. Bio. 34: 49-55 [Abstract] [Full Text]  
• Gonzalez-Alegre, P., Bode, N., Davidson, B. L., Paulson, H. L. (2005). Silencing Primary Dystonia: Lentiviral-Mediated RNA Interference Therapy for DYT1 Dystonia. J. Neurosci. 25: 10502-10509 [Abstract] [Full Text]  
• GOVAN, V A (2005). Strategies for Human Papillomavirus Therapeutic Vaccines and Other Therapies Based on the E6 and E7 Oncogenes. Ann. N. Y. Acad. Sci. 1056: 328-343 [Abstract] [Full Text]  
• Pichler, A., Zelcer, N., Prior, J. L., Kuil, A. J., Piwnica-Worms, D. (2005). In vivo RNA Interference-Mediated Ablation of MDR1 P-Glycoprotein. Clin. Cancer Res. 11: 4487-4494 [Abstract] [Full Text]  
• Gregory, R. I., Shiekhattar, R. (2005). MicroRNA Biogenesis and Cancer. Cancer Res. 65: 3509-3512 [Abstract] [Full Text]